Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII
- PMID: 19903856
- DOI: 10.1158/0008-5472.CAN-09-1778
Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal primary human brain tumor. GBMs are characterized by a variety of genetic alterations, among which oncogenic mutations of epidermal growth factor receptor (EGFRvIII) is most common. GBMs harboring EGFRvIII have increased proliferation and invasive characteristics versus those expressing wild-type (wt) EGFR. To identify the molecular basis of this increased tumorgenic phenotype, we used iTRAQ-labeling differential proteomic analysis. Among several differentially expressed proteins, we selected CRMP1, a protein implicated in cellular invasion that was markedly decreased in GBMs expressing EGFRvIII, for further study. The differential expression of CRMP1 was confirmed in a panel of human GBM cell lines and operative specimens that express wtEGFR or mutant EGFRvIII by quantitative real-time PCR, Western blot, and immunohistochemical analysis. In human GBM samples, decreased expression of CRMP1 correlated with EGFRvIII positivity. Knockdown of CRMP1 by siRNA resulted in increased invasion of wtEGFR expressing human GBM cells (U87 and U373) to those found in isogenic GBM cells. Exogenous expression of EGFRvIII in these wtEGFR-expressing GBM cells promoted their ability to invade and was accompanied by decreased expression of CRMP1. Rescuing CRMP1 expression decreased invasion of the EGFRvIII-expressing GBM cells by tilting the balance between Rac and Rho. Collectively, these results show that the loss of CRMP1 contribute to the increased invasive phenotype of human GBMs expressing mutant EGFRvIII.
Similar articles
-
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.Cancer Res. 2006 Jan 15;66(2):867-74. doi: 10.1158/0008-5472.CAN-05-2753. Cancer Res. 2006. PMID: 16424019
-
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.Clin Cancer Res. 2002 Sep;8(9):2894-901. Clin Cancer Res. 2002. PMID: 12231534
-
Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.Cancer Res. 2009 Oct 1;69(19):7548-56. doi: 10.1158/0008-5472.CAN-08-4783. Epub 2009 Sep 22. Cancer Res. 2009. PMID: 19773446
-
The EGFRvIII variant in glioblastoma multiforme.J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. J Clin Neurosci. 2009. PMID: 19324552 Review.
-
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. FEBS J. 2013. PMID: 23777544 Review.
Cited by
-
Co-occurrence and Mutual Exclusivity Analysis of DNA Methylation Reveals Distinct Subtypes in Multiple Cancers.Front Cell Dev Biol. 2020 Jan 29;8:20. doi: 10.3389/fcell.2020.00020. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32064261 Free PMC article.
-
Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF) Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ).Biomed Res Int. 2020 Nov 23;2020:9237381. doi: 10.1155/2020/9237381. eCollection 2020. Biomed Res Int. 2020. PMID: 33299887 Free PMC article.
-
Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme.Mol Cancer. 2013 Jul 15;12:74. doi: 10.1186/1476-4598-12-74. Mol Cancer. 2013. PMID: 23855374 Free PMC article.
-
Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer.Transl Oncol. 2020 Mar;13(3):100746. doi: 10.1016/j.tranon.2020.100746. Epub 2020 Feb 24. Transl Oncol. 2020. PMID: 32105991 Free PMC article.
-
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration.Ther Adv Med Oncol. 2020 Apr 28;12:1758835920915302. doi: 10.1177/1758835920915302. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32426045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous